Oklo stock tumbles as Financial Times scrutinizes valuation
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Chief Operating Officer Eben Tessari sold 12,368 shares of the company’s Class A Ordinary Shares on October 14, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold in two transactions with prices ranging from $37.65 to $37.99, netting $465,843.
On the same day, Tessari exercised options to acquire 6,500 Class A Ordinary Shares at a price of $8.83, for a total value of $57,395.
In other recent news, Kiniksa Pharmaceuticals reported strong financial results for the second quarter of 2025, highlighting a significant 52% increase in net revenue compared to the previous year. The company’s net revenue reached $156.8 million, driven by its strategic focus on ARCALYST and an expanding clinical portfolio. These developments underscore Kiniksa’s growth trajectory, with the company benefiting from its flagship product’s performance. Additionally, analysts have been closely monitoring the company’s progress, although there have been no reported upgrades or downgrades at this time. The recent financial results reflect a positive outlook for Kiniksa Pharmaceuticals, as it continues to build on its current momentum. These developments are part of the company’s ongoing efforts to enhance its market position and deliver value to its stakeholders. Investors are keeping a close watch on Kiniksa’s next moves following these impressive results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.